Only the study by Lantazi et al. analyzed the efficacy of targeted therapy in NM and SSM patients and demonstrated a decreased survival for BRAF-mutated NM as compared with BRAF-mutated SSM patients, and histologic subtype NM in the multivariate analysis was independently associated with a decreased survival. Here, BRAF is linked to superficial spreading melanoma.